Secondary (subgroup) analysis of phase 3 VALIANT in 55 adolescents with C3G or primary IC-MPGN: pegcetacoplan reduced UPCR by 75% vs placebo at 26 weeks (nominal P<0.001), with stable eGFR; 3 per group had serious adverse events.
Secondary analysisn = 55
Vivarelli et al. Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis